Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, also known as nonstructural protein 12 (nsp12), is a central enzyme in the coronavirus replication and transcription machinery. It catalyzes the synthesis of viral RNA from an RNA template, a process essential for viral genome replication and subgenomic mRNA production. For full activity, nsp12 forms a complex with accessory proteins nsp7 and nsp8. RdRp operates within the larger replication-transcription complex (RTC), which includes other nonstructural proteins. Due to its essential role in virus propagation, RdRp is considered one of the most promising antiviral drug targets against COVID‑19.
Nucleotide analog inhibitors bind to the active site, are incorporated into nascent viral RNAs, and cause premature termination or stalling.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA-dependent RNA Polymerase (SARS-CoV-2) (RdRp).